Sherbrooke Park Advisers LLC Cuts Holdings in Elanco Animal Health Incorporated (NYSE:ELAN)

Sherbrooke Park Advisers LLC lessened its position in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 67.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 18,631 shares of the company's stock after selling 38,456 shares during the period. Sherbrooke Park Advisers LLC's holdings in Elanco Animal Health were worth $226,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. FMR LLC increased its stake in shares of Elanco Animal Health by 1,153.6% in the fourth quarter. FMR LLC now owns 40,232,327 shares of the company's stock valued at $487,213,000 after buying an additional 37,022,891 shares during the period. Dimensional Fund Advisors LP increased its position in Elanco Animal Health by 6.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 17,900,987 shares of the company's stock valued at $216,774,000 after purchasing an additional 1,074,274 shares during the period. Magnetar Financial LLC increased its position in Elanco Animal Health by 13.7% during the 4th quarter. Magnetar Financial LLC now owns 12,032,325 shares of the company's stock valued at $145,711,000 after purchasing an additional 1,454,082 shares during the period. Geode Capital Management LLC raised its holdings in Elanco Animal Health by 4.0% during the 4th quarter. Geode Capital Management LLC now owns 8,180,840 shares of the company's stock worth $99,102,000 after purchasing an additional 312,165 shares during the last quarter. Finally, The Manufacturers Life Insurance Company lifted its position in shares of Elanco Animal Health by 8.4% in the 4th quarter. The Manufacturers Life Insurance Company now owns 6,924,098 shares of the company's stock worth $83,851,000 after purchasing an additional 538,631 shares during the period. 97.48% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. Stifel Nicolaus increased their price objective on shares of Elanco Animal Health from $15.00 to $16.00 and gave the stock a "buy" rating in a research report on Monday, May 19th. Morgan Stanley cut their price target on shares of Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating on the stock in a research report on Wednesday, February 26th. Barclays decreased their price target on Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating for the company in a report on Wednesday, February 26th. UBS Group dropped their price objective on Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating on the stock in a research note on Wednesday, February 26th. Finally, Piper Sandler cut their target price on Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating on the stock in a research report on Thursday, March 6th. Four investment analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $15.17.

Elanco Animal Health Stock Down 0.1%

NYSE:ELAN traded down $0.01 during trading hours on Monday, reaching $12.66. The company had a trading volume of 4,743,380 shares, compared to its average volume of 5,073,930. Elanco Animal Health Incorporated has a twelve month low of $8.02 and a twelve month high of $18.80. The company has a quick ratio of 1.31, a current ratio of 2.55 and a debt-to-equity ratio of 0.66. The firm has a market cap of $6.29 billion, a price-to-earnings ratio of 31.66, a P/E/G ratio of 2.50 and a beta of 1.49. The business's 50-day simple moving average is $10.34 and its two-hundred day simple moving average is $11.42.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported $0.37 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.31 by $0.06. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The company had revenue of $1.19 billion for the quarter, compared to analysts' expectations of $1.17 billion. During the same quarter in the prior year, the firm earned $0.34 EPS. The business's revenue was down 1.0% on a year-over-year basis. On average, equities analysts expect that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Insider Activity

In other Elanco Animal Health news, Director Lawrence Erik Kurzius acquired 10,000 shares of Elanco Animal Health stock in a transaction dated Tuesday, March 11th. The stock was purchased at an average cost of $10.20 per share, for a total transaction of $102,000.00. Following the completion of the acquisition, the director now directly owns 111,459 shares of the company's stock, valued at $1,136,881.80. This represents a 9.86% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 0.89% of the company's stock.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.